First, although the cohort size is reasonable for a rare tumor entity such as TETs, it remains limited and precludes multivariate survival analyses to assess the potential prognostic value of TEAD4 expression while adjusting for relevant clinical and pathological cofactors. Here, TEAD4 is linked to neoplasm.